In this online CME self-learning program:
Migraine headache is the leading condition of recurrent cephalalgias of moderate or severe intensity. It is the most common type of headache presented by patients that seek medical treatment, and the World Health Organization (WHO) has ranked migraine in the top fifteen most disabling medical conditions. The condition has been identified as one of the most common neurological disorders, and in the United States, its prevalence in the general population is approximately 12%. In children, the prevalence ranges from 1% to 4% and does not present more commonly in either sex. However, after menarche, its prevalence in females (18%) is approximately three times higher than in males.
While the mechanism behind migraine headaches was long thought to be the result of cerebral arterial vasoconstriction and reactive vasodilation, that theory has since been discredited. More recently, research points in the direction of trigeminovascular activation of pain receptors located throughout the central nervous system. Irrespective of cause however, migraine has long been underdiagnosed in the United States in spite the availability of accepted guidelines for diagnostic criteria and effective agents for prophylaxis and treatment.
There have been a wide array of advances in the realm of migraine management with respect to pharmacotherapeutic options, including both presently approved as well as more novel, potential ones on the horizon. Helping the clinician discern the role of each of agent – present and future – merits continuing healthcare professional education.
Healthcare professionals who are: primary care physicians, neurologists, headache specialists, nurse practitioners, physician assistants, nurses, OB-GYN specialists, pharmacists, and those who otherwise commonly care for or clinically encounter patients who may experience migraine headache.
This program is supported by an educational grant from Amgen and Promius Pharma.
Release Date: August 08, 2016 -- Expiration Date: August 08, 2018
Faculty: George Sarka, MD
By the end of the session the participant will be able to:
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Dr. George Sarka, MD has received financial support from Genzyme.
Disclosures of Educational Planners: Charles Turck, PharmD is an officer and part owner of ScientiaCME, LLC with no relevent financial disclosures.
Commercial Support Disclosure: This program is supported by an educational grant from AMGEN and Promius Pharma.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Multiple Sclerosis (MS) and Its Complications: Highlights from the American Academy of Neurology 2016 Annual Meeting (AAN 2016) : Take-Aways, Emerging Practice Changes, and Barriers to their Implementation